ClinicalTrials.gg
CompletedNCT05138562Updated Aug 13, 2024

TUC3PII-01_TU2670 Phase IIa Clinical Study

A Phase 2 interventional study of Placebo Comparator: Placebo and Active Comparator: TU2670 320mg in Endometriosis, sponsored by TiumBio Co., Ltd.. Completed at 40 sites in 5 countries. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by TiumBio Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Endometriosis with a site in Poland — 3 open to participants now, 4 under way, none of them phase 3. Endometriosis · Poland.

Enrollment
20th of 27
86 · median 187
Started
2021
with 3 others
Phase 2
14 of 29
none open now
Registered
21st of 29
by date

Among the 29 studies in Endometriosis with a site in Poland, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2021, is one of 14 in phase 2, and was the 21st registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

3 of the 29 studies in Endometriosis with a site in Poland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Endometriosis with a site in Poland, or all of them as a file.
02

Study summary

This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe endometriosis-associated pain.

Read the detailed description

Treatment Groups and Duration:

Following a washout period of up to 12 weeks, subjects will enter a screening period of up to 12 weeks including an observation period consisting of a complete menstrual cycle.

Subjects will be randomly assigned in a 1:1:1:1 ratio to receive either 12 weeks of TU2670 320 mg QD, TU2670 240 mg QD, TU2670 120 mg QD, or matching placebo. TU2670 or a matching placebo will be administered in the clinic on Day 1. Subjects in the PK subset population will also receive the following additional doses in the clinic: Day 2 (after collection of the 24-hour PK sample); the dose on the day scheduled for subsequent serial PK sample collection (Week 4 or Week 5); and the next scheduled dose (after collection of the 24-hour PK sample). All other doses can be taken by the subject at home. Following the end of treatment, subjects will be followed up for safety for 12 weeks.

Statistical Methods:

All formal statistical tests will be done at the 5% 2-sided significance level. Point estimates will have 2 sided 95% confidence intervals (CIs) where applicable.

Where appropriate, variables will be summarized descriptively (frequency and percent will be summarized for categorical variables; n (number of available subjects), mean, standard deviation [SD], median, minimum, and maximum will be presented for continuous variables) by study visit and by treatment group.

Statistical summaries will be presented for the changes from baseline to each time point in efficacy endpoints that it is applicable.

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Independent Ethics Committee (IEC)-approved written /assent and privacy language as per national regulations must be voluntarily obtained from the subject.
  • Premenopausal female subject, 18 to 45 years, inclusive
  • Subject has moderate to severe endometriosis-related pain

Exclusion criteria

Exclusion Criteria:

  • Subject has used hormonal or other drugs with effects on gynecological endocrinology within 12 weeks
  • Subject has been nonresponsive to GnRH-agonist or antagonist therapy for the management of endometriosis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    4 Placebo capsules

    Drug: Placebo Comparator: Placebo

  • Active comparator
    TU2670 High Dose

    320mg, QD

    Drug: Active Comparator: TU2670 320mg

  • Active comparator
    TU2670 Medium Dose

    240 mg, QD

    Drug: Active Comparator: TU2670 240mg

  • Active comparator
    TU2670 Low Dose

    120 mg, QD

    Drug: Active Comparator: TU2670 120mg

Interventions

  • DrugPlacebo Comparator: Placebo

    4 x placebo capsules, QD

  • DrugActive Comparator: TU2670 320mg

    320mg (80mg x 4), QD

  • DrugActive Comparator: TU2670 240mg

    240mg (80mg x 3 + placebo x 1), QD

  • DrugActive Comparator: TU2670 120mg

    120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD

06

What researchers measure

Primary outcomes

  1. overall pelvic pain

    Change from baseline to 12 weeks of treatment of the mean dysmenorrhea score (defined as mean overall pelvic pain score on menstrual bleeding days) as measured by the Numeric Rating Scale(minimum 0, maximum 10, higher score mean a worse outcome) over the past month.

    Time frame: 12 weeks

Secondary outcomes

  1. mean Numeric Rating Scale pain score

    Change from baseline to 12 weeks of treatment of the mean Numeric Rating Scale pain score(minimum 0, maximum 10, higher score mean a worse outcome) for non-menstrual pelvic pain (mean Numeric Rating Scale pain score on non menstrual bleeding days)

    Time frame: 12 weeks

  2. mean overall pelvic pain Numeric Rating Scale pain score

    Change from baseline to 12 weeks of treatment of the mean overall pelvic pain Numeric Rating Scale pain score (mean Numeric Rating Scale pain score(minimum 0, maximum 10, higher score mean a worse outcome) over all 28 days)

    Time frame: 12 weeks

  3. mean Numeric Rating Scale dyspareunia score

    Change from baseline to 12 weeks of treatment of the mean Numeric Rating Scale((minimum 0, maximum 10, higher score mean a worse outcome) dyspareunia score

    Time frame: 12 weeks

  4. rescue medication

    Change from baseline to 12 weeks of treatment of the use of protocol-defined rescue medication (ie, ibuprofen)

    Time frame: 12 weeks

  5. Time to increase of dose of rescue medication

    Time to increase of dose of rescue medication from 0 week to 12 weeks

    Time frame: 12 weeks

  6. Time to decrease of dose of rescue medication

    Time to decrease of dose of rescue medication from 0 week to 12 weeks

    Time frame: 12 weeks

  7. Modified Biberoglu and Behrman sign and symptom scores

    Change from baseline to 12 weeks of treatment of the Modified Biberoglu and Behrman (mB\&B) sign and symptom scores(minimum 0, maximum 3, higher score mean a worse outcome)

    Time frame: 12 weeks

  8. Patient Global Impression of Change

    Patient Global Impression of Change (minimum 1, maximum 7, higher score mean a worse outcome) at 12 weeks of treatment

    Time frame: 12 weeks

  9. Endometriosis Health Profile-5

    Change from baseline to 12 weeks of treatment in the Endometriosis Health Profile-5 score(minimum 1(Never), maximum 5(Always), higher score mean a worse outcome)

    Time frame: 12 weeks

  10. 36-Item Short Form Health Survey

    Change from baseline to 12 weeks of treatment of the 36-Item Short Form Health Survey(Scoring meaning is different from the questions but usually lower score mean a worse outcome)

    Time frame: 12 weeks

  11. Work Productivity and Activity Impairment Questionnaire: General Health

    Change from baseline to 12 weeks of treatment of the Work Productivity and Activity Impairment Questionnaire: General Health (Scoring meaning is different from the questions)

    Time frame: 12 weeks

Other outcomes

  1. Bone mineral density loss

    Change from baseline to 12 weeks of treatment of the bone mineral density as assessed by dual-energy X-ray absorptiometry (DXA)

    Time frame: 12 weeks

07

Study locations

40 sites
  • University Hospital Hradec Kralove
    Hradec Králové, Hradec Kralove 50005, Czechia
  • Kestr-gyn s.r.o., Gynekologicka ambulance
    Náchod, Nachod 54701, Czechia
  • OB/GYN
    Praha, Praha 1 11000, Czechia
  • Vseobecna fakultni nemocnice v Praze, Dept. of Gynekologicko- porodnickaklinika 1.LF UK
    Praha, Praha 2 128 08, Czechia
  • Fakultni Nemocnice Kralovske Vinohrady
    Praha 10, Praha 10034, Czechia
  • University Hospital Brno
    Brno, 62500, Czechia
  • NEUMED gynekologicka ambulance
    Olomouc, 77900, Czechia
  • Nemocnice Na Bulovce
    Prague, 18100, Czechia
  • Università degli Studi di Cagliari - Policlinico Universitario Duilio Casula
    Monserrato, Cagliari 09042, Italy
  • Azienda ospedaliero-universitaria Senese
    Siena, Tuscany 53100, Italy
  • University of Florence
    Florence, 50129, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano
    Milano, 20122, Italy
  • AZIENDA Ospedaliero Univeritaria Di Modena
    Modena, 41124, Italy
  • Fondazione Policlinico Universitario A. Gemelli IRCCS
    Roma, 00168, Italy
  • P.O. Sant'Anna
    Torino, 10126, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, 37126, Italy
  • Dolnośląskie Centrum Ginekologii
    Wrocław, Dolnośląskie 53333, Poland
  • In Vivo sp. z o.o.
    Bydgoszcz, Kujawsko-pomorskie 85090, Poland
  • Gameta Hospital
    Rzeszów, Lodzkie 95030, Poland
  • Komed Centra Kliniczne
    Lublin, Lubelskie 20362, Poland
  • Hospital Pro-Familia
    Rzeszów, Podkarpackie 35-302, Poland
  • Prywatna Klinika Położniczo-Ginekologiczna Sp. z o.o.
    Białystok, Podlaskie 15224, Poland
  • Centrum Medyczne Mikołowska
    Katowice, Silesia 40065, Poland
  • Examen sp z o.o.
    Skorzewo, Wielkopolska 60185, Poland
  • Klinika Leczenia Niepłodności, Ginekologii i Położnictwa Bocian
    Białystok, 15267, Poland
  • Provita Sp. z o.o.
    Katowice, 40611, Poland
  • Klinika Leczenia Niepłodności, Ginekologii i Położnictwa Bocian, Fertility Clinic
    Poznań, 60529, Poland
  • Ural Research Institution of Maternity and Child Care of Russian Public Health Ministry
    Ekaterinburg, Sverdlovskaya Oblast 620146, Russian Federation
  • State Institution of Healthcare Moscow City Clinical Hospital # 13 of Moscow Department
    Moscow, 115280, Russian Federation
  • FSHI Clinical Hospital #85 of FMBA
    Moscow, 115409, Russian Federation
  • Moscow State University of Medicine and Dentistry
    Moscow, 127473, Russian Federation
  • SBIH Leningrad Regional Clinical Hospital
    Saint Petersburg, 194291, Russian Federation
  • Ivano-Frankivsk National Medical University on the basis of the municipal non-profit enterprise Ivano-Frankivsk Regional Perinatal Center of the Regional Council
    Ivano-Frankivs'k, Ivano-Frankivsk 76018, Ukraine
  • Communal non-commercial enterprise Vinnytsia City Clinical Hospital "Center of Mother and the Child
    Vinnytsia, Vinnitsia 21019, Ukraine
  • Communal Nonprofit Enterprise Maternity Hospital#4 of Zaporizhzhya Municipal Council
    Zaporizhzhya, Zaporizhzhya Oblast 69065, Ukraine
  • State Scientific Institution Center for Innovative Medical Technologies of the National Academy of Sciences of Ukraine
    Kiev, 04053, Ukraine
  • Kyiv city clinical hospital #9, Department of gynecology
    Kyiv, 04112, Ukraine
  • Lviv city clinical hospital #4
    Lviv, 79005, Ukraine
  • Danylo Halytskyy Lviv national medical university
    Lviv, 79010, Ukraine
  • Private Small-Scale Enterprise Medical Centre Pulse
    Vinnytsia, 21001, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jan 2024, 29 months.

Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Dec 1, 2021
StartActual
Aug 19, 2021
Primary completionActual
Jan 23, 2024
CompletionActual
Aug 5, 2024
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05138562
Lead sponsor
TiumBio Co., Ltd.
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Aug 19, 2021
Primary completion
Jan 23, 2024
Completion
Aug 5, 2024
Last update
Aug 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion